chronic hepatitis B
Conditions
Interventions
Case series:After long-term nucleoside (acid) treatment
Sponsors
Nanfang hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 60 years old male or female; 2. Patients signed the informed consent form; 3. For HBeAg positive patients, therapy with nucleos(t)ide analogs should be received for at least 24 months with undetectable HBV DNA, normal ALT and HBeAg seroconversion; 4. For HBeAg negative patients, therapy with nucleos(t)ide analogs should be received for at least 36 months with undetectable HBV DNA and normal ALT; 5. Patients diagnosed as compensatory liver disease and with no evidence of liver cirrhosis before the therapy; 6. Patients with WBC > 3.5G/L, PLT > 100G/L, AFP < 20ng/ml, normal ALT and AST, and undetectable HBV DNA at base line; 7. Patient agreed not to participate in any other study.
Exclusion criteria
Exclusion criteria: Patientss who met any of the following criteria will not be eligible to this study; 1. The researchers consided that the patient could not comply with the study; 2. Patients with decompensated liver disease; 3. Patients with liver cirrhosis; 4. Patients with other viruses coninfection, such as HCV, HDV, HIV and autoimmune liver disease; 5. Patients with autoimmune diseases, cancer, other important organ dysfunctions and other serious complications; 6. Patients who had a liver transplant or plan to receive liver transplantation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| virological response;biochemical response;serological response; | — |
Countries
China
Contacts
Public ContactJie Peng
NanFang hospital
Outcome results
None listed